Cervical cancer screening strategies: Advancements and current practices.

Mary Lake Polan*

Department of Oncology, Yale University Medical School, South Africa

Introduction

Cervical cancer remains one of the most common cancers affecting women globally, with approximately 604,000 new cases and 342,000 deaths reported in 2020 according to the World Health Organization (WHO). Effective screening is pivotal in reducing the incidence and mortality associated with this malignancy. Over the past few decades, strategies for cervical cancer screening have evolved significantly, incorporating advances in technology, epidemiological understanding, and public health strategies [1].

Traditionally, cervical cancer screening has relied on the Papanicolaou (Pap) smear test, developed in the 1940s by George Papanicolaou. This method involves collecting cells from the cervix and examining them under a microscope for abnormalities indicative of cancer or precancerous changes. The Pap smear has been instrumental in reducing cervical cancer mortality by detecting pre-cancerous changes early, allowing for effective treatment [2].

Despite its success, the Pap smear has limitations, including variability in interpretation and the need for regular, often yearly, screening to maintain efficacy. Additionally, it is less sensitive for detecting certain types of high-grade lesions. These limitations have spurred the search for more effective screening strategies.

Human papillomavirus (HPV) testing has revolutionized cervical cancer screening. HPV, particularly types 16 and 18, is responsible for the majority of cervical cancer cases. HPV testing detects the presence of high-risk HPV strains in cervical cells, providing a direct indication of the risk of developing cervical cancer. This approach is highly sensitive and has shown greater accuracy than cytology alone in detecting high-grade cervical lesions [3].

The integration of HPV testing with cytology, known as co-testing, has become a standard screening strategy. The American Cancer Society (ACS) and other health organizations recommend co-testing every five years for women aged 30 to 65. This method balances sensitivity and specificity, enhancing the detection of high-grade lesions while reducing false positives and unnecessary procedures.

Primary HPV testing, where HPV testing is conducted without preceding cytology, has gained traction, particularly in regions with high cervical cancer burden. This strategy is endorsed by the WHO and many health bodies due to its high sensitivity for detecting cervical intraepithelial neoplasia (CIN) grade 2 or higher, a precursor to cancer. Primary HPV testing simplifies the screening process, reducing the need for repeated testing and potentially lowering healthcare costs[4].

Recent studies and trials, such as the ATHENA study, have demonstrated that primary HPV testing alone is as effective, if not more so, than cytology-based screening. The key advantage is its ability to identify high-risk individuals with fewer false negatives. Countries like Australia and the Netherlands have adopted primary HPV testing as their primary screening method, reporting significant reductions in cervical cancer incidence and mortality [5].

The landscape of cervical cancer screening continues to evolve with technological advancements. Liquid-based cytology (LBC) has largely supplanted conventional smear techniques, offering better sample preservation and higher diagnostic accuracy. LBC allows for the simultaneous testing of HPV DNA and cytology on the same sample, streamlining the screening process and enhancing diagnostic precision.

Molecular testing techniques, such as the use of DNA methylation markers and transcriptomics, are being explored to enhance the specificity and sensitivity of HPV tests. These technologies aim to refine screening protocols, potentially identifying women at the highest risk of developing cervical cancer and tailoring screening intervals accordingly [6].

Furthermore, novel biomarkers and machine learning algorithms are being investigated to improve the accuracy of screening tests. These innovations hold promise for developing non-invasive screening methods, such as self-sampling kits that could be administered at home, thereby increasing screening uptake, particularly in underserved populations.

Despite advances in screening technologies, significant disparities in cervical cancer incidence and mortality persist, particularly in low- and middle-income countries (LMICs). The WHO's Global Strategy to Accelerate the Elimination of Cervical Cancer aims to reduce incidence and mortality rates by 90% and 70%, respectively, by 2030. This strategy emphasizes the importance of HPV vaccination, screening, and treatment of precancerous lesions [7].

***Correspondence to**: Mary Lake Polan, Department of Oncology, Yale University Medical School, South Africa, United States, Email: marylakepolan@gmail.com

***Received**: 22-Apr-2024, Manuscript No. AAGGS-24-138561; **Editor assigned**: 26-Apr-2024, PreQC No. AAGGS-24-138561(PQ); **Reviewed**: 11-May-2023, QC No. AAGGS-24-138561; Revised: 18-May-2024, Manuscript No. AAGGS-24-138561 (R); **Published**: 25-May-2024, DOI:10.35841/2591-7994-8.3.208*

***Citation:** Polan ML. Cervical cancer screening strategies: Advancements and current practices. 2024;8(3):208*

Implementing effective screening programs in LMICs presents challenges, including limited healthcare infrastructure, lack of trained personnel, and inadequate resources. To address these issues, international organizations and health bodies are promoting innovative approaches, such as task-shifting to non-physician health workers and integrating cervical cancer screening with other maternal and child health services [8].

Cervical cancer screening has made tremendous strides over the years, transitioning from traditional cytology to advanced HPV testing and molecular diagnostics. The shift towards primary HPV testing and the exploration of new biomarkers and technologies herald a new era in cervical cancer prevention. While challenges remain, particularly in ensuring equitable access to screening in resource-limited settings, the global health community's concerted efforts are crucial in achieving the goal of cervical cancer elimination [9].

Continued research, innovation, and international collaboration are essential to overcoming existing barriers and advancing towards a world where cervical cancer is no longer a leading cause of death among women. Through these concerted efforts, the vision of a cervical cancer-free future is increasingly within reach [10].

References

1. Fox H, Buckley CH. The endometrial hyperplasias and their relationship to endometrial neoplasia.Histopathology. 1982;493-510.
2. Grimelius L. A silver nitrate stain for alpha-2 cells in human pancreatic islets. Acta Soc Med Ups. 1968;73:243-270.
3. Burger RA, Brady MF, Bookman MA, Gini F Fleming, Bradley J Monk, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
4. Albores-Saavedra J, Rodríguez-Martínez HA, Larraza-Hernández. Carcinoid tumors of the cervix.Pathol Annu. 1979;14: 273-291.
5. Ueda G, Yamasaki M, Inoue M, et al. Immunohistological demonstration of calcitonin in endometrial carcinomas with and without argyrophil cells.Nihon Sanka Fujinka Gakkai Zasshi. 1980; 32:960-964.
6. Tateishi R, Wada A, Hayakawa K, et al. Argyrophil cell carcinomas (apudomas) of the uterine cervix. Light and electron microscopic observations of 5 cases.Virchows Arch A Pathol Anat Histol. 1975;366: 257-274.
7. Proks C, Feit V. Gastric carcinomas with argyrophil and argentaffin cells.Virchows Arch A Pathol Anat Histol. 1982;395: 201-206.
8. Partanen S, Syrjänen K. Argyrophilic cells in carcinoma of the female breast.Virchows Arch A Pathol Anat Histol. 1981;391:45-51.
9. Fetissof F, Dubois MP, Arbeille-Brassart B, et al. Argyrophilic cells in mammary carcinoma.Hum Pathol. 1983;14:127-134.
10. Gibbs NM. Incidence and significance of argentaffin and paneth cells in some tumours of the large intestine.J Clin Pathol. 1967;20: 826-831.

Citation: *Polan ML. Cervical cancer screening strategies: Advancements and current practices. 2024;8(3):208*